Roxana Schillaci

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 11

Top Venues

Cell death & disease

Journal for immunotherapy of cancer

Cancers

Oncoimmunology

Instituto de Biología y Medicina Experimental-CONICET

University of Buenos Aires (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Instituto de Biología y Medicina Experimental-CONICET Feb 01 1995

Argentina

Senior Researcher :: Laboratory of Molecular Mechanisms of Carcinogenesis

Education History

University of Buenos Aires Mar 01 1987 - Jul 08 1993

Argentina

PHD :: Immunology

Publications

Santiago Madera, Franco Izzo, María F Chervo, Agustina Dupont, Violeta A Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F Mercogliano, Cecilia Jazmín Proietti, Roxana Schillaci, Patricia V Elizalde, Rosalía I Cordo Russo
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Cell death & disease 14 (12) (2023)
Sofia Bruni, Florencia L Mauro, Cecilia Jazmín Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. Journal for immunotherapy of cancer 11 (3) (2023)
Sofia Bruni, Florencia L Mauro, Cecilia Jazmín Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. Journal for immunotherapy of cancer 11 (3) (2023)
María Florencia Mercogliano, Sofia Bruni, Florencia Luciana Mauro, Roxana Schillaci
Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers 15 (7) (2023)
Sofia Bruni, Florencia L Mauro, Cecilia Jazmín Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. Journal for immunotherapy of cancer 11 (3) (2023)
Santiago Madera, Franco Izzo, María F Chervo, Agustina Dupont, Violeta A Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F Mercogliano, Cecilia Jazmín Proietti, Roxana Schillaci, Patricia V Elizalde, Rosalía I Cordo Russo
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Cell death & disease 14 (12) (2023)
Santiago Madera, Franco Izzo, María F Chervo, Agustina Dupont, Violeta A Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F Mercogliano, Cecilia Jazmín Proietti, Roxana Schillaci, Patricia V Elizalde, Rosalía I Cordo Russo
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Cell death & disease 13 (5) (2022)
María Florencia Mercogliano, Sofía Bruni, Florencia Mauro, Patricia Virginia Elizalde, Roxana Schillaci
Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. Cancers 13 (3) (2021)
Mara De Martino, Mercedes Tkach, Sofia Bruni, Darío Rocha, María F Mercogliano, Mauro E Cenciarini, María F Chervo, Cecilia Jazmín Proietti, Florent Dingli, Damarys Loew, Elmer A Fernández, Patricia V Elizalde, Eliane Piaggio, Roxana Schillaci
Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. Oncoimmunology 9 (1) (2020)
Santiago Madera, María F Chervo, Violeta A Chiauzzi, Matías G Pereyra, Leandro Venturutti, Franco Izzo, Agustina Roldán Deamicis, Pablo Guzman, Agustina Dupont, Juan Carlos Roa, Mauro E Cenciarini, Sabrina Barchuk, Silvina Figurelli, Daniel Lopez Della Vecchia, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Teresa Castiglioni, Eduardo Cortese, Sandra Ares, Ernesto Gil Deza, Felipe G Gercovich, Cecilia Jazmín Proietti, Roxana Schillaci, Rosalía I Cordo Russo, Patricia V Elizalde
Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis. Hormones & cancer 11 (5-6) (2020)
Lorena M Coria, Andrés E Ibañez, Mercedes Tkach, Florencia Sabbione, Laura Bruno, Marianela V Carabajal, Paula M Berguer, Paula Barrionuevo, Roxana Schillaci, Analía S Trevani, Guillermo H Giambartolomei, Karina A Pasquevich, Juliana Cassataro
A Brucella spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses. Journal of immunology (Baltimore, Md. : 1950) 196 (10) (2016)

Roxana Schillaci.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Roxana Schillaci